These findings are consistent with the recent reports that CD109 upregulation promotes stemness properties of non-SCC cancer cells such as lung adenocarcinoma cells [37] and that CD109 positive cancer cells exhibit higher tumorigenicity in epithelioid sarcoma [43], triple-negative breast cancer [44], and cervical squamous cell carcinoma [21]. This evidence concerns the gene CD109 and triple-negative breast carcinoma.